Alex Kilbertus

Alex Kilbertus

Auto-generated profile, based on publicly available information

Alex Kilbertus

Department of Dermatology and Venerology, Kepler University Hospital, Johannes Kepler University, Linz, Austria

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
JTJakub Trizuljak
Jakub Trizuljak
WSWolfgang R. Sperr
Wolfgang R. Sperr
LNLucie Nekvindová
Lucie Nekvindová
HEHanneke Oude Elberink
Hanneke Oude Elberink
KGKaroline V. Gleixner
Karoline V. Gleixner
Peter ValentPeter Valent
Peter Valent

1 April 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
DFDavid Fuchs
David Fuchs
AKAlex Kilbertus
Alex Kilbertus
KKKarin Kofler
Karin Kofler
NBNikolas von Bubnoff
Nikolas von Bubnoff
KSKhalid Shoumariyeh
Khalid Shoumariyeh
Peter ValentPeter Valent
Peter Valent
Mastocytosis in adults often presents with skin lesions. A bone marrow biopsy (BMB) is necessary to confirm or exclude the presence of systemic mastocytosis (SM) in these cases. When a BMB is not performed the provisional diagnosis is mastocytosis in the skin (MIS). No generally accepted scoring system has been established to estimate the risk of SM in these patients. To develop a risk score to predict SM in adults with MIS. We examined 1145 patients with MIS from the European Competence Network on Mastocytosis (ECNM) registry who underwent a BMB. 944 patients had SM and 201 patients had cutaneous mastocytosis (CM); 63.7% were female, 36.3% were male. Median age was 44±13.3 years. The median serum tryptase level amounted to 29.3±81.9 ng/ml. We established a multivariate regression model using the whole population of patients as a training and validation set (bootstrapping). A risk score was developed and validated with receiver operating curves. In the multivariate model, the tryptase level (p<0.001), constitutional/cardiovascular symptoms (p=0.014) and bone symptoms/osteoporosis (p<0.001) were independent predictors of SM (p<0.001, sensitivity 90.7%, specificity 69.1%). A 6-point risk score was established (risk, 10.7-98.0%) and validated. Using a large dataset of the ECNM registry we created a risk score to predict the presence of SM in patients with MIS. Although the score will need further validation in independent cohorts, our score seems to discriminate safely between patients with SM and with pure CM.